Furthermore, a longitudinal analysis of serum matrix metalloproteinase-9 (MMP-9) levels revealed a significant and persistent increase (up to 2 weeks after recovery) in this marker of BBB disruption among COVID-19 patients with neurological sequelae, compared to severe COVID-19 patients and healthy controls [82]. The gene discussed is MMP9; the disease is COVID-19.